Tucuxi

Your companion to make personalized drug treatments

Product Contact

About Tucuxi

Drug are traditionally prescribed at a standard dosage whatever the patient profile…

Many drugs are traditionally prescribed at standard dosage despite a high variability of their absorption and disposition between patients. For critical drugs (anticancer, anti-HIV, antifungals, anti-epileptics, psychotropic agents etc.), too low concentrations may lead to inefficacy and sometimes selection of drug-resistant cells or viruses. Conversely, too high concentrations increase the risks of adverse effects and toxicity. Such drugs are said to have a “narrow therapeutic margin”.

Monitoring of circulating drug concentrations in the patients, also called “therapeutic drug monitoring” (TDM), represents the best way to optimize drug dosage and prevent toxicity or lack of effectiveness, when no accurate efficacy markers are measurable. Still TDM has slowly developed until recently, because both the drug measurement and the interpretation of concentration results were demanding. During the last decade, laboratory technologies have markedly progressed and no longer represent a limiting factor. At present, dozens of drugs can be easily analyzed. A prerequisite for the wide accessibility of TDM to all patients that require it is that physicians, pharmacists, nurses and even patients can easily interpret drug concentration results and adjust therapies accordingly.

Tucuxi is a unique software solution for the optimization of drug treatments by health professionals, based on concentration monitoring:

  • Its natural workflow makes it of unequaled user-friendliness.
  • Its versatility enables it to accommodate almost any drug, for which population pharmacokinetic-pharmacodynamic data are available.
  • Its graphical presentation of concentration results makes the clinical interpretation of TDM crystal-clear.
  • Its connectivity to laboratory information systems enables its full integration in the analytical process.

Tucuxi is the result of several years of research and development. Its development was initiated by the Service of clinical pharmacology of the university hospital of Lausanne (CHUV) in Switzerland, a precursor and active contributor in TDM. Its implementation was conducted by the School of management and engineering of the canton Vaud.

This project has been funded by Nano-Tera.ch, CHUV and HEIG-VD, as part of the ISyPeM2 project.